Alersa s.r.o.
- Address
- Marsala Koneva 985/1, 040 22 Košice, Slovakia
Alersa s.r.o. - Allergic and Immunologic Disease Research Center
Alersa s.r.o. is a specialized medical research center dedicated to advancing the understanding and treatment of allergic and immunologic disorders. The center demonstrates particular expertise in conducting clinical trials for chronic inflammatory conditions affecting both pediatric and adult populations. Their comprehensive research portfolio encompasses innovative therapeutic approaches ranging from biologic therapies to novel small molecule inhibitors.
- Chronic urticaria and spontaneous urticaria research, including biosimilar studies and novel targeted therapies
- Severe and uncontrolled asthma trials evaluating combination inhaler therapies and exacerbation prevention strategies
- Allergic rhinoconjunctivitis research with focus on pediatric allergen immunotherapy
- Atopic dermatitis studies in pediatric populations comparing advanced systemic therapies
The center's research focus emphasizes improving outcomes for patients with inadequately controlled allergic conditions despite standard therapy. Their trial experience spans multiple study phases, including both Phase IIIb and Phase III investigations, demonstrating capability in late-stage clinical development. Alersa s.r.o. shows particular commitment to pediatric research, with multiple studies involving children and adolescents, reflecting their expertise in managing the unique challenges of conducting clinical trials in younger populations with allergic and immunologic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Novartis Pharma AG2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alersa s.r.o.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis | Novartis Pharma AG | Phase II | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 2 | Unknown | 2025-04-04 | 2026-04-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.